Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates  by Abaasa, Andrew et al.
C
o
i
A
F
a
b
c
a
A
R
R
A
A
K
H
I
V
S
S
E
I
1
s
a
E
(
E
(
(
h
0
0Vaccine 34 (2016) 1778–1785
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
omparison  of  HIV  incidence  estimated  in  clinical  trial  and
bservational  cohort  settings  in  a  high  risk  ﬁshing  population
n  Uganda:  Implications  for  sample  size  estimates
ndrew  Abaasaa,∗,  Gershim  Asikia, Matthew  A.  Priceb,c, Eugene  Ruzagiraa,
reddie  Kibengoa,  Ubaldo  Bahemukaa, Patricia  E.  Fastb, Anatoli  Kamali a
MRC/UVRI, Uganda Research Unit on AIDS, Entebbe, Uganda
International AIDS Vaccine Initiative, New York, USA
University of California at San Francisco, Department of Epidemiology and Biostatistics, San Francisco, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 22 November 2015
eceived in revised form 15 February 2016
ccepted 17 February 2016
vailable online 2 March 2016
eywords:
IV
ncidence
accines
ample
ize
stimate
mplications
a  b  s  t  r  a  c  t
Background:  Clinical  trial participants  may  differ  from  the  source  population  due  to the demands  of  trial
participation  and  self-selection,  inadvertent  selection  of  a lower-risk  group,  or both.  We  investigated  the
HIV risk status  of  volunteers  in  a Simulated  Vaccine  Efﬁcacy  Trial (SiVET)  nested  within  a  prospective
observational  cohort  of ﬁsher  folks  in South  Western  Uganda.
Methods:  Volunteers  aged 18–49  years,  at high  risk  for  HIV from  ﬁshing  communities  in Masaka  district
were  recruited  into  an  observational  cohort  and  followed  quarterly.  High  risk  was deﬁned  as  a  self-report,
of at  least  one  of the  following  in  the  past  three  months;  sexually  transmitted  infections,  unprotected
sex  with  >1  partner  or a new  sexual  partner,  use  of  recreational  drugs,  weekly  alcohol  use, and/or  fre-
quent travel.  Volunteers  who  had  at least  three  months  of  follow-up  in the  observational  cohort  were
consecutively  enrolled  in SiVET,  administered  Hepatitis  B  vaccine  at months  (0, 1, 6)  and  followed-up
three  days  post  vaccinations  to  mimic  a vaccine  trial schedule.  HIV  incidence  over  the  next  12  months
was  compared  between  SiVET  and  the observational  cohort  studies.
Results:  Between  January  2012  and  February  2013,  575  individuals  were  enrolled  in  the  observational
cohort,  of  whom  282  were enrolled  in SiVET  between  July 2012  and  February  2013.  Despite  similar
pattern of  reported  risk  behaviour  in  both  studies,  HIV incidence  was  higher  in  observational  cohort,  11.4
cases/100  PYO  [95%  CI: 7.4–17.7]  compared  to 3.8  [95%  CI: 2.0–7.0]  in SiVET  (p  <  0.01).  SiVET volunteers
tended  to be men,  having  some  education  and  longer-term  residents,  all factors  that  are  also  associated
with  lower  HIV  risk.
Conclusion: We  observed  a lower  HIV  incidence  in  SiVET  than  in  the observational  cohort.  The  two  popu-
lations  differed  signiﬁcantly  in  demographics  but  not  in reported  risk.  HIV  incidence  estimates  from
observational  cohorts  must  be used  with  caution  to estimate  the  trial  study  size.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. IntroductionIdentifying populations with high HIV incidence and adequate
tudy retention is necessary to perform HIV vaccine efﬁcacy tri-
ls that have sufﬁcient statistical power [1]. The investigators of
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the International AIDS Vaccine Initiative (IAVI) network in sub-
Saharan Africa have been conducting a number of observational
studies to assess the suitability and willingness of potential popu-
lations to enrol in future HIV vaccine efﬁcacy trials [2]. Volunteers
in these observational cohorts have included discordant couples,
members of ﬁshing communities, women at high risk, and men
who have sex with men  (MSM). In these studies, annual HIV
incidence ranged from 1.1 to 10.8 per 100 person years of obser-
vation (PYO) with one-year study retention of 75–97% [2] and
HIV prevalence ranged from 8.3% to 16.4% [2]. These populations
have also expressed a high willingness to enrol in future efﬁ-
cacy trials [3–5]. Other studies in high risk populations in the
same region have found HIV prevalence ranging between 6.1%
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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nd 37% [6–10] and annual HIV incidence between 4% and 12.6%
er 100 PYO [7,11,12]. Microbicide trials among women at high
isk of HIV infection identiﬁed from sero-discordant relation-
hips residing in areas far from the ﬁshing populations but in the
ame district observed HIV incidence in the control arm rang-
ng between 3.3 and 4.3 per 100 PYO [13,14]. Although ﬁshing
opulations have been identiﬁed as possible high risk popula-
ion for future efﬁcacy trials, no trials have been conducted yet
n these populations. These populations have unique character-
stics such as high mobility and excessive alcohol consumption
hat may  impact on both HIV incidence and study retention dur-
ng trials [9,11]. In such populations, HIV incidence reported from
bservational cohorts or feasibility studies is usually used to esti-
ate the required sample size for efﬁcacy trials [12]. However,
uch data may  not reﬂect the incidence in an efﬁcacy trial because
f changes in the eligibility criteria for participation and trial
rocedures such as risk reduction counselling, mandatory use of
ontraceptives and condom provision, more frequent visits and
he difference in duration between observational studies and efﬁ-
acy trials. Inadvertent selection of lower risk volunteers into a
rial could also play a role [12]. In Uganda [13], Nigeria [15] and
hana [16] microbicide and a pre exposure prophylaxis (PrEP)
17] trials have shown lower HIV incidence in the control arm
han that observed in feasibility cohort studies at the planning
tage [12,15–17]. One systematic review [18] reported a number
f HIV prevention studies that were unsuccessful or terminated
ecause they found lower HIV incidence and statistical power than
hat was predicted based on observational data. These under-
owered studies expose volunteers to investigational products in
xperiments of limited clinical value, waste time and ﬁnancial
esources [19,20]. It is important, therefore, to obtain more accu-
ate estimates of the actual incidence that would occur during trial
onditions.
To our knowledge, there is no data that have compared HIV
ncidence in an observational cohort to that in an efﬁcacy trial
sing the ﬁshing populations that are potentially being consid-
red for future trials. In this analysis, we compared HIV incidence
n a longitudinal HIV vaccine preparedness observational cohort
o that in a Simulated Vaccine Efﬁcacy Trial (SiVET) nested within
he cohort. These two studies were part of collaboration between
he Medical Research Council/Uganda Virus Research Institute
MRC/UVRI) Uganda Research Unit on AIDS and the International
IDS Vaccine Initiative (IAVI) to prepare for future vaccine efﬁcacy
rials.
. Methods
.1. Study population
We  used data from an observational ﬁshing cohort and from
 nested Simulated Vaccine Efﬁcacy Trial (SiVET) to compare HIV
ncidence between the two studies in rural South-Western Uganda.
he observational cohort was established to estimate annual HIV
ncidence and maintain a pool of volunteers for possible recruit-
ent into future efﬁcacy trials. Enrolment for the observational
ohort was between January 2012 and February 2013. The SiVET
tudy mimicked an HIV vaccine efﬁcacy trial using a licensed Hep-
titis B vaccine as a proxy for an HIV vaccine to assess retention
nd willingness to participate in future trials. Enrolment into the
iVET started in July 2012; and ended in February 2013 when the
stimated sample had been accrued. In this analysis, we included
bservational cohort volunteers that had been enrolled by the date
iVET completed enrolment. We  included data for every volunteer
rom the 3 month visit date to 12 months later. Each volunteer in
he two studies contributed at most 12 months of follow up data or (2016) 1778–1785 1779
to the point they were last seen or tested HIV positive, if that was
shorter.
2.2. Observational cohort procedures
Volunteers in the observational cohort were recruited from ﬁsh-
ing communities located about 40 km from the MRC/UVRI research
site in Masaka town by trained ﬁeldworkers. Fieldworkers visited
each household on the lakeshore, offered HIV counselling and test-
ing (HCT). Male and female adults aged (18–49 years) identiﬁed as
HIV negative through HCT were screened for high risk of acquiring
HIV. High risk was deﬁned as a self-report of any of the follow-
ing in the previous three months: sexually transmitted infections
(STIs), unprotected sex with more than one or a new sexual part-
ner, use of recreational drugs and/or at least weekly alcohol use,
and absence from home for at least three consecutive nights per
week. Eligible volunteers and at high risk were referred to the
MRC/UVRI study clinic for enrolment and subsequent quarterly
follow up visits. At the clinic, interviewer-administered case report
forms were used to record locator details (physical location and
phone contacts), demographics, risk behaviour characteristics, and
medical assessments. Medical assessments and HCT were repeated
every 3 months. HIV risk was assessed every 6 months and at annual
visit, volunteers whose risk proﬁle had changed to low risk were
withdrawn from the cohort. Volunteers were reminded by phone
call and followed by a home visit if they missed their clinic appoint-
ments. Cohort volunteers were considered as lost to follow up and
withdrawn from the cohort if they failed to attend two  sequential
follow up visits. A lost to follow up volunteer was readmitted into
the cohort if they came back to the study clinic and still fulﬁlled the
eligibility criteria.
2.3. SiVET procedures
When volunteers presented for their 3 month visits in the
observational cohort, they were assessed for recruitment into
SiVET. SiVET inclusion criteria included; having spent at least three
months in the observational cohort, no contraindications for Hep-
atitis B vaccine and, if female, willingness to use contraception until
3 months after the last vaccination. Recruitment was  stopped at
accrual of the estimated sample size when 291 had been screened
and 282 enrolled. Of the nine volunteers screened and not enrolled,
three were pregnant, two  refused to consent and four did not show
up for enrolment (Fig. 1). Volunteers in SiVET continued with their
procedures and schedules in the parent observational cohort. SiVET
visits were synchronised with observational cohort visits. In addi-
tion to the parent observational cohort procedures and schedules
SiVET volunteers were administered a licensed Hepatitis B vaccine
(ENGERIX-BTM GlaxoSmithKline Biologicals Rixensart, Belgium,)
following the standard schedule of 0, 1 and 6 months, akin to what
might happen in an HIV vaccine trial. At each vaccination visit, vol-
unteers were kept in the clinic for observation of reactogenicity
events for at least 30 min  after vaccination and asked to return
to the clinic after 3 days for further review. Each volunteer was
followed for 12 months aligned to the period SiVET was conducted.
2.4. Laboratory methods
Rapid HIV testing was performed by Determine (Alere, Medi-
cal Co., Ltd, Matsuhidai, Matsudo-shi, Chiba, Japan) and all positive
specimens were conﬁrmed by two ELISA tests (Vironostika HIV
Uni-Form II plus 0 microelisa system, Biomerieux, Boxtel, The
Netherlands and Murex HIV-1.2.0, Murex, Biotech Limited, Dart-
ford, UK). A western blot was  performed if ELISA results were
discordant.
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575 enro lle d  
473 completed at least 3months in observational 
cohort  
283 e ligible  to cont inue in the Observ ational  
282 enrolled into SiVET 
845 scre ened for ob serv ational  cohort   
270 Not en rol led 
       Low HIV risk (237) 
       Other (33) 
102 reached 3 months in observational cohort after 
SiVET fully enrolled (i.e., not invited into SiVET)
291 scre ened for Si VET 
9 Not enrolled   
   Pregnan t (3) 
   Refused (2) 
  Did not return in time 
for enrolment (4)
10 HIV+  172 either missed their 
appointment or reported 
late to  the  clini c
• Seen at months 0, 1 and 6 (vaccination 
visits) a nd at day 3 afte r every 
vaccination  
• Addi tiona l fo llo w up  at  month s 3, 9 
and 12   
Seen ever y 3 months for  
one year   
139  
Lost to  follow up (52)  
Withdrawn (low risk) (13) 
Withdrawn (HIV+)  (18) 
Miss ed last visit  (61) 
210  
Lost to  follow up (13)  
Withdrawn (other reasons) (11 ) 
Withdrawn (HIV+)  (7) 
Miss ed last visit  (41) 
Completed  12 months    
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tig. 1. Study proﬁle of enrolment and follow up of 575 ﬁsher folk enrolled in an obse
.5. Statistical analysis
Data were analysed in Stata 12.0 (StataCorp, College Station, TX,
SA). Volunteer characteristics in the two studies were summari-
ed using frequencies and percentages. Chi-square tests were used
o compare demographic and clinical characteristics between the
wo studies at baseline. Person-years of observation (PYO) were
alculated as the sum of the time from baseline to the date of the
ast HIV-uninfected result, or to the estimated date of HIV infection
or each volunteer. Date of HIV infection was estimated as the mid-
oint of the interval between the last HIV-uninfected and the ﬁrst
IV-infected result date. The HIV incidence was estimated as num-
er of HIV infections divided by the person time at risk. Hazard
atios with 95% conﬁdence interval (CI) to assess the association
etween factors and incidence were obtained using cox propor-
ion hazard regression models. To estimate factors associated with
IV incidence, we carried out a bivariate analysis and all factors for
hich the association attained statistical signiﬁcance (p < 0.15) on
og likelihood test were included in the initial multivariable model.
ex and age were included a priori. Factors were retained in the
ultivariable model if the log likelihood test p-value of inclusion
f a factor was less than 0.05..6. Ethical considerations
Both studies were approved by the Uganda Virus Research Insti-
ute (UVRI) Research Ethics Committee and the Uganda Nationalnal cohort and a Simulated Vaccine Efﬁcacy Trial (SiVET) in South Western Uganda.
Council for Science and Technology. Written informed consent was
sought from each volunteer, and a separate informed consent pro-
cedure was performed for each study. Volunteer conﬁdentiality
was maintained throughout the follow up period. Volunteers that
acquired HIV were immediately referred for care to local HIV care
service providers of their choice.
3. Results
3.1. Screening and enrolment
A total of 845 individuals were screened for eligibility into
the observational cohort from January 2012 to February 2013; of
whom, 575 (68.0%) were enrolled (Fig. 1). The primary reason for
exclusion was  low self-reported HIV risk (n = 237). After being fol-
lowed for 3 months in the observational cohort, 172 either missed
their appointment for SiVET enrollment or reported late to the
clinic, and 10 had sero-converted. By the time SiVET enrollment was
completed, an additional 102 volunteers had not yet made their 3
months visit in the observational cohort. Of 575 in the observational
cohort, a total of 291 were consecutively screened and 282 enrolled
in SiVET between July 2012 and February 2013. Nine volunteers
were screened but not enrolled into SiVET because of pregnancy (3),
refusal (2) and no show for enrolment (4) (Fig. 1). Except for the 282
volunteers that enrolled in SiVET and 10 that had sero-converted,
the rest (283) remained in the observational cohort. Retention was
82.0% and 72.6%, p = 0.02 at the 12 month visit in SIVET and the
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Table  1
Baseline socio-demographic characteristics of 575 volunteers enrolled from a ﬁshing community into an observational cohort and a Simulated Vaccine Efﬁcacy Trial (SiVET)
in  southwestern Uganda.
Socio-demographic characteristics Observational (n = 283)
n  (%)
SiVET (=282)
n (%)
P-value
Sex
Male 137 (48.4) 205 (72.7) <0.01
Female 146 (51.6) 77 (27.3)
Age  (years)
18–24 127 (44.9) 88 (31.2) <0.01
25–34 115 (40.6) 127 (45.0)
35–49 41 (14.5) 67 (23.8)
Tribe
Baganda 114 (40.3) 128 (45.4) 0.22
Other  169 (59.7) 154 (54.6)
Education
≥Primary school 248 (87.6) 263 (93.3) 0.02
None 35 (12.4) 19 (6.7)
Religion
Christian 216 (76.3) 217 (77.0) 0.86
Muslim 67 (23.7) 65 (23.0)
Marital status
Single 86 (30.4) 84 (29.8) 0.15
Married 125 (44.2) 143 (50.7)
Separated/widowed 72 (25.4) 55 (19.5)
Occupation
Fishing and ﬁshing related business 135 (47.7) 197 (69.9) <0.01
Other  148 (52.3) 82 (29.1)
Residence in ﬁshing community (years)
0–1 96 (34.0) 48 (17.0) <0.01
>1–5  132 (46.6) 121 (42.9)
>5  55 (19.4) 113 (40.1)
Sex  while drunk
Never 144 (68.6) 198 (70.2) 0.72
Always 66 (31.4) 84 (29.8)
Genital discharge
Yes 51 (24.3) 32 (11.3) <0.01
No  159 (75.7) 250 (88.7)
Genital sores
Yes 58 (27.6) 46 (16.3) <0.01
No  152 (72.4) 236 (83.7)
Number of partners
0–1 150 (71.4) 180 (63.8) 0.10
2+  60 (28.6) 102 (36.2)
New partner
No 145 (69.0) 193 (68.4) 0.90
Yes  65 (31.0) 89 (31.6)
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uCondom use with new partner
Never 33 (50.8) 
Always 32 (49.2) 
bservational cohort respectively. The reasons for not attending
isits were similar in both studies (Fig. 1).
Investigating possible differences between volunteers that were
creened for SiVET and those that were not, the sub analysis showed
hat volunteers in the observational cohort that were not screened
or SiVET because of either missing or reporting late for their
hree month visit had higher proportion of females 49.2% vs 28.9%,
 < 0.01, more persons aged 18–24 years 43.0% vs 31.6%, p = 0.04,
ad more recent immigrants (having less than one year) to the
shing community 29.1% vs 17.5%, p < 0.01, had been absent from
ome for at least three consecutive nights per week 51.7% vs 39.3%,
 = 0.01 and engaged in other businesses (not ﬁshing or ﬁshing
elated) 51.5% vs 30.2%, p < 0.01. There were no differences in terms
f education, tribe, religion and marital status (Supplementary
able 1).
Supplementary Table 1 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.vaccine.2016.02.
48..2. Baseline characteristics
Table 1 shows the socio-demographic characteristics of the vol-
nteers enrolled in both studies. Although the observational cohort35 (39.3) 0.19
54 (60.7)
study was  the source of enrolment for SiVET, some volunteer char-
acteristics differed between the two studies. While there were
equal proportions of men  and women  enrolled in the observa-
tional cohort, more men  (72.7% vs 48.4%, p < 0.01) were enrolled
in SiVET. Observational cohort included relatively younger volun-
teers (44.9% vs 31.2% aged under 24 years, p < 0.01), those who  had
no formal education (12.4% vs 6.7%, p = 0.02), a lower proportion
directly engaged in ﬁshing or ﬁshing related business (47.7% vs
69.9%, p < 0.01), had fewer number of years (recent immigrants)
spent in the ﬁshing community (34.0% vs 17.0%, p < 0.01), more with
genital discharge (24.3% vs 11.3%, p < 0.01) and more with genital
sores (27.6% vs 16.3%, p < 0.01). Other characteristics including: reli-
gious faith, tribe, marital status, having sex while drunk, number of
sexual partners, having a new sexual partner and condom use with
a new partner were similar in the two  studies.
3.3. Risky behaviour and clinical characteristics
The behavioural and clinical characteristics at baseline, 6 and 12
months of follow-up in both studies are shown in Fig. 2. Between
0 and 12 months, there was minimal reduction (<10%) of risky
behaviour or self-reported STIs, within each study and this was  not
statistically signiﬁcantly different.
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Fig. 2. Report of risky behaviour and clinical characteristics of HIV high risk 
.4. HIV incidence
During the initial period of at least 3 months of the observational
ohort, prior to enrolment of SiVET there were 10 sero-converters
ver 203.3 PYO of follow-up giving incidence rate (IR) of 4.9 cases
er 100 PYO (95% CI: 2.6–9.1). During the subsequent 12 months of
ollow up in the observational cohort, 20 sero-conversions occurred
uring 175.5 PYO of follow up [IR = 11.4 cases per 100 PYO (95% CI:
.4–17.7)] while in SiVET 10 sero-conversions in 264.2 PYO were
bserved [IR = 3.8 cases per 100 PYO (95% CI: 2.0–7.0)]. Incidence
ate ratio (IRR) comparing observational cohort to SiVET was  3.0
95% CI: 1.3–7.2, p < 0.01). In both studies, women had a higher HIV
ncidence point estimate than men, though this did not achieve
tatistical signiﬁcance: 14.9 per 100 PYO (95% CI: 8.6–25.6) com-
ared to 7.9 per 100 PYO (95% CI: 3.8–16.6) in observational cohort
p = 0.09), and 4.2 per 100 PYO (95% CI: 1.4–13.2) vs 3.6 per 100
YO (95% CI: 1.7–7.6) in SiVET (p = 0.18). The HIV incidence among
omen in the observational cohort was 3 times higher than that
mong women in SIVET (14.9 per 100 PYO vs 4.2 per 100 PYO,
 = 0.04); The IR among men  in the observational cohort was  two
imes that of men  in SIVET (7.9 per 100 PYO vs 3.6 per 100 PYO
 = 0.05).
.5. Factors associated with HIV incidence
Factors that remained independently associated with increased
isk of HIV acquisition in multivariable analysis in the observational
ohort included lack of education and shorter length of stay (new
mmigrants) in the ﬁshing village. In SiVET, only shorter length of
tay (new immigrants) in the ﬁshing villages was  independently
ssociated with HIV acquisition (Table 2).
.6. Hypothetical sample size estimates for observational cohort
nd SiVET and effect on study power
To understand the effect of the difference in HIV incidence
etween observational cohort and SiVET in the context of future
accine efﬁcacy trials in this community, we did hypothetical
ower calculations as below. We  assumed that an efﬁcacy trial
eeds to demonstrate a 50% reduction in HIV incidence with 80%
ower and a two-sided alpha = 0.05. Based on incidence from theonths (6) 12-Months  (12 )
folk enrolled in an observational cohort and SiVET in south western Uganda.
observational cohort (11.4 per 100 PYO), a sample size of 1274 (637
in each trial arm) would be required. If we used the SiVET HIV inci-
dence of 3.8 per 100 PYO, we would require a sample size of 4140
(2070 in each trial arm) which would ultimately decrease the study
power of the estimates drawn from the observational cohort to
about 30%.
4. Discussion
We  found a threefold greater HIV incidence in the obser-
vational cohort than SiVET study. In this comparative analysis,
volunteers were drawn from the same population and were fol-
lowed under similar conditions, although the SiVET had more
study visits including vaccination and post vaccination visits. The
reported risk behaviours in the two  studies were similar, highlight-
ing the potential challenges of relying on self-report for risk data
[21]. We  did observe that self-reported genital discharge and sores
were higher among observational cohort volunteer than SiVET at
baseline; GU discharge and sores were not associated with HIV
incidence (though our study was  not powered to test this asso-
ciation). The large difference in HIV incidence may  be in part due
to the differences in the volunteer demographic proﬁle at recruit-
ment. SiVET study recruited fewer women, more individuals with
formal education and lower proportion of recent immigrants. We
also observed that, apart from volunteer sex, which was borderline
associated, these factors were independently associated with lower
HIV incidence and thus may  have contributed to the lower SiVET
HIV incidence. Kiwanuka et al. [3] and Seeley et al. [11], in these
same communities and communities further north of lake Victoria
near Entebbe, have previously shown that recent immigration to
these ﬁshing communities is associated with high HIV incidence.
The HIV incidence in these studies was  3.4 per 100 Person years
at risk (pyar) [3] and 4.9 per 100 pyar [11] respectively. However,
these studies did not ﬁnd association with sex and did not assess
the effect of education.
Generally, ﬁshing communities have the highest HIV prevalence
and incidence [6,7,9,11] compared to inland agricultural commu-
nities [22] in this region. They have retention comparable to stable
inland agricultural communities [3,23]. The ﬁshing communities
are characterised by high mobility, multiple sexual partnerships
arising from exchange of sex for cash and transactional sex, very
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Table  2
HIV incidence, unadjusted and adjusted factors associated with HIV incidence among 575 people living in the ﬁshing community enrolled in an observational and SiVET
cohorts in South Western Uganda.
Characteristics Observational cohort Simulated Vaccine Efﬁcacy Trial
Incidence per 100PY uHR aHR Incidence per 100PY uHR aHR
Overall 11.4 3.8
Sex
Male  7.9 1 1 3.1 1 1
Female  14.9 1.7 (0.7–4.4) 1.9 (0.9–4.0) 5.7 1.8 (0.5–6.4) 1.4 (0.4–5.5)
Age  (years)
18–24 9.5 1 1 3.6 1 1
25–34  10.5 0.9 (0.3–2.8) 1.5 (0.6–3.7) 3.4 0.9 (0.2–4.1) 1.3 (0.3–5.9)
35–48 19.0 2.0 (0.6–6.2) 2.5 (0.9–6.5) 4.9 1.3 (0.3–6.7) 1.9 (0.4–9.9)
Tribe*
Baganda 13.6 1 0.8 1 1
Other  10.1 0.7 (0.3–1.7) 6.3 7.5 (1.0–58.8) 6.6 (0.8–52.8)
Education¥
≥Primary school 9.4 1 1 3.8 1
None  33.1 3.9 (1.4–10.5) 3.1 (1.3–7.7)* 5.3 1.5 (0.2–11.7)
Religion
Christian 11.2 1 2.4 1
Muslim 11.9 0.9 (0.3–2.5) 8.5 3.4 (0.9–11.9)
Marital status
Single 6.1 1 5.0 1
Married 9.9 1.4 (0.4–5.5) 1.5 0.3 (0.1–1.6)
Separated 19.5 3.2 (0.9–11.6) 7.8 1.5 (0.4–5.9)
Occupation
Fishing and related business 10.7 1 2.6 1
Other  12.0 1.3 (0.5–3.1) 6.7 2.6 (0.7–9.0)
Residence in ﬁshing community (years)¥
0–1 18.4 1 1 9.4 1 1
>1–5  8.2 0.5 (0.2–1.2) 0.5 (0.2–1.2)* 5.3 0.6 (0.2–2.0) 0.5 (0.1–1.9)
>5  9.7 0.4 (0.1–1.5) 0.3 (0.1–0.8)* 0 – –
Sex  while drunk
Never 9.7 1 3.4 1
Always 20.6 2.2 (0.6–7.6) 5.0 1.4 (0.2–11.2)
Genital discharge
Yes 12.5 1 3.4 1
No  10.1 0.8 (0.3–2.3) 3.5 1.0 (0.1–8.4)
Genital sores
Yes 14.4 1 7.0 1
No  9.4 0.7 (0.2–1.8) 2.8 0.4 (0.1–1.8)
Number of partners
0–1 10.9 1 3.6 1
2+  10.3 0.9 (0.3–2.7) 3.3 0.9 (0.2–3.8)
New  partner
No 10.8 1 3.8 1
Yes  12.7 1.2 (0.4–3.2) 2.8 0.8 (0.2–4.0)
Condom use with new partner
Never 13.6 1 3.2 1
Always 11.9 0.8 (0.2–3.9) 4.3 1.4 (0.1–15.0)
uHR unadjusted Hazard ratio, p-likelihood p-value, aHR-adjusted Hazard ratio.
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¥ Both unadjusted and adjusted p < 0.05.
uid marital relationships, high alcohol consumption and a low HIV
isk perception due to more imminent dangers such as drowning
hat are perceived to as the main risk of death [3]. All these factors
ediate the HIV risk and raise their risk proﬁle.
The HIV incidence of 3.8 per 100 Person years observed in SiVET
s similar to that observed in other microbicide prevention stud-
es in the area (ranging between 3 and 4.5 per 100 person years)
13,14]. For one microbicide study a preceding feasibility study had
bserved an HIV incidence of 12.6 per 100 person years [12] but
ssumed an incidence of 4 per 100 person years similar to our
ssumptions of risk reduction. The lower incidence observed dur-
ng the microbicide trial was as anticipated at the design and in
greement with our ﬁndings. However our ﬁndings do not seem to
uggest this difference resulted from risk reduction but rather from
he selection criteria at recruitment.
The implication of this ﬁnding is that enrolment of volunteers
rom ﬁshing communities into trials may  exclude certain residents
hrough self-selection or other means which may  in turn affect theincidence in the trial. In our study, it seems that selection into the
study played a greater role as the demographic proﬁle of SiVET
study volunteers suggested a lower risk group. Because of con-
secutive enrolment of the most available individuals into SiVET,
volunteers who were likely to enrol were those who were more
likely to be on time for the SiVET enrolment visit. They were less
likely to miss visits or get lost to follow up. Those that did not enrol
were likely to be frequent travellers, younger individuals, women,
new immigrants and those engaged in non-ﬁshing related occu-
pation. These have been shown to be associated with high HIV
incidence in the previous cohorts [3,11] and/or in this compara-
tive analysis. Community-based observational studies from which
HIV incidence estimates are derived should be considered with this
in mind to best avoid risk of low statistical power. Careful consider-
ation of recruitment strategies, source populations, and community
outreach and engagement is important to ensure that previous HIV
incidence estimates are appropriate for sample size determination.
Failure to achieve target parameters used to design a trial could
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ead to inconclusive results or termination of the trial as observed
n previous HIV prevention trials [15,16].
In a meta-analysis of trials that were terminated or had incon-
lusive or negative results due to loss of statistical power, risky
ehaviour reduction and other exceptional HIV prevention proce-
ures performed in the control arm were advanced as reasons for
ower incidence of outcome measures [18]. In contrast, our study
id not show differences in reduction of reported risky behaviours
etween the observational cohort and SiVET. In our study, it seems
rocedures used to select volunteers enrolled into SiVET played a
reater role in creating volunteer differences between the two stud-
es. SiVET volunteers were also seen more frequently, including a
ne-month vaccination visit, and a visit three days following each
f the three vaccination visits (enrolment, month 1 and month 6). At
he additional non-vaccination visits, volunteers were reassessed
or any adverse events. However, these additional visits seem not
o have altered the risk proﬁle of the volunteers in the SiVET study.
There are some limitations of our comparative analysis. Vol-
nteers in the SiVET study were recruited from the observational
ohort after 3 months of participation in this cohort (i.e., at
he cohort’s ﬁrst follow up visit). Similar approach was followed
including data from the month three visit) while analysing the
bservational cohort data. Although in an actual efﬁcacy trial vol-
nteer enrolment may  be delayed after screening, it is unlikely to
e up to 3 months. It is unlikely that nearly half of the available
opulation will be enrolled into a given trial like it was  the case
n this observational cohort where half went into the trial. Volun-
eers were not randomised to joining SiVET or remaining in the
bservational cohort. Randomisation could have helped eliminate
he imbalance in the demographic proﬁle. However, it could have
mpaired our ability to rapidly complete SiVET enrolment. We  also
ropped volunteers from the observational cohort who reported
ow risk behaviour, and did not do this as part of the SiVET. This
ay  have served to “enrich” the observational cohort for volun-
eers at greater risk of acquiring HIV, however only 13 (<5% of the
ohort) low risk volunteers were dropped from follow up. Addi-
ionally, our analysis was not well powered for the multivariable
nalysis, particularly among the SiVET volunteers, because of the
mall number of HIV sero-converters in this study. Thus, while
e may  have observed differences in point estimates, some large
ifferences failed to achieve statistical signiﬁcance (e.g., HIV inci-
ence across volunteer sex). However, this is a rare example of a
imulated trial being conducted alongside an observational cohort
rawn from the same source population under study procedures
onducted by the same study staff, and it is important to draw what
essons we can.
We have demonstrated that HIV incidence derived from obser-
ational cohorts must be considered carefully when estimating the
ample size for an efﬁcacy trial to avoid under powering the trial.
n our hypothetical example, if you used incidence from the obser-
ational cohort to estimate the trial study size, you would have
chieved only about 30% power. We  suggest two approaches to
chieving sufﬁcient power for trials conducted in this community:
i) if you used historical cohorts’ data to estimate a study sample
ize, you would only be off by about 50% or less. Therefore, adjusting
he study size to take into consideration the predicted lower inci-
ence for the trial could be a useful strategy. (ii) Using recruitment
trategies that focus on known predictors of HIV acquisition, such
s recruiting and retaining recent immigrants and volunteers with
ow education. Another lesson learnt is that the risk assessment
uestionnaire answers are not reliable.uthors’ contribution
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